Hone vs Marek Health vs Maximus Tribe: TRT Clinic Comparison

Hone Health, Marek Health, and Maximus Tribe are the three most recognizable cash-pay TRT telehealth platforms in 2026, and they are pitched at three different patients. Hone is the 50-state generalist for the busy professional with a classic low-T workup. Marek is the optimization power-user platform with the deepest lab menu in the category. Maximus is the enclomiphene-first axis-preservation play built around men who either want fertility preserved or want to avoid HPG-axis shutdown. None of the three accepts insurance for TRT — all are cash-pay subscriptions stacked on top of medication cost. This page maps the trade-offs against the Endocrine Society 2018 diagnostic standard (Bhasin^[1]) and the TRAVERSE cardiovascular-safety dataset (Lincoff 2023^[2]).

The honest summary

• All three clear the diagnostic bar. Each clinic requires lab confirmation of low testosterone before prescribing. The Endocrine Society 2018 standard is total T below 300 ng/dL on two separate morning measurements plus consistent symptoms (Bhasin^[1]). Maximus specifies the required panel verbatim: “Total Testosterone, SHBG (or free testosterone), LH, PSA, and Hematocrit.” Hone covers “40+ key biomarkers” across hormones and metabolic markers. Marek's panel through Marek Diagnostics covers “80+ Biomarkers tested.”
• Hone is the volume player. Premium membership is $155/month plus medication, advertised as “Chosen by 95% of patients,” with a $25/month Basic tier for retests-only patients. The lab panel is broad but not the deepest in the category — the bet is convenience plus 50-state coverage.
• Marek leads on lab breadth. The Marek Diagnostics Total Health Panel Comprehensive runs $595 for 80+ biomarkers covering hormonal, metabolic, cardiovascular, and organ-function markers, with optional genetic add-ons (Androgen Receptor Sensitivity $500, APOE Genotyping $200, MTHFR DNA $225). The lab menu is à la carte and standalone, so a patient can buy the panel without committing to the membership.
• Maximus is the axis-preservation specialist. Five distinct testosterone protocols are catalogued: Enclomiphene-Only, Oral Testosterone, Testosterone Cream plus Enclomiphene, Injectable TRT, and Injectable TRT plus hCG. The Injectable TRT pathway uses subcutaneous injection, not just intramuscular — “Maximus offers subcutaneous injections, which are just as effective as intramuscular and often more comfortable.”
• Cardiovascular safety is class-level reassuring. TRAVERSE (Lincoff 2023 NEJM^[2]) randomized 5,246 hypogonadal men age 45–80 with cardiovascular disease or risk to transdermal testosterone 1.62% gel vs placebo for a mean of 22 months. Primary MACE was non-inferior (HR 0.96, 95% CI 0.78–1.17). Secondary signals for atrial fibrillation, acute kidney injury, and pulmonary embolism warrant monitoring at every clinic.

Hone Health: the 50-state generalist

Hone Health publishes its pricing transparently. Per the live pricing page (verified 2026-05-28), Basic membership is $25/month and Premium is $155/month, with the marketing line “Chosen by 95% of patients” on the Premium tier. Both tiers are billed “plus cost of medication.” Premium membership covers “Advanced testing for 40+ key biomarkers,” “A private, telehealth consult with licensed physicians,” “Personalized protocols: testosterone, estrogen, weight loss & more,” and “Retesting + follow-ups every 90 days.” The biomarker categories shown are Hormones, Heart, Brain, Liver, Kidneys, Immunity, Metabolism, and Nutrients.

Hone's workflow is the cleanest of the three for a man who knows he has classic low-T symptoms and wants standard testosterone cypionate without paying for tests he will not read. At-home capillary blood-draw kits ship to the patient, or the patient can complete a Quest in-person draw. Once labs return below the Endocrine Society threshold and a physician consult confirms symptoms, a prescription is written and shipped from a partner pharmacy. The 90-day retest cadence aligns with the Endocrine Society monitoring guidance (Bhasin^[1]) on hematocrit, PSA, and total T after dose changes.

What Hone is not optimized for: patients who want the full adrenal axis (cortisol AM, DHEA-S), full thyroid panel (free T3, free T4, reverse T3), or peptide-stack ancillaries. Those patients self-select into Marek. Hone also does not feature an enclomiphene-only pathway as prominently as Maximus, so men prioritizing fertility preservation typically end up at Maximus.

Marek Health: the optimization power-user platform

Marek Health's main marketing site is fully client-side rendered, which means the dollar tier of the membership is not server-side scrapeable as of 2026-05-28 — we have flagged the exact monthly membership figure as needs-direct-confirmation. What is verifiable live is the Marek Diagnostics arm at marekdiagnostics.com, which sells the lab work à la carte: the Total Health Panel Comprehensive is $595 for “80+ Biomarkers tested” covering “hormonal balance, metabolic function, cardiovascular health, and organ function.” The panel is offered in Comprehensive, Complete, and Executive tiers, with optional 45-minute lab-review calls.

The lab menu is what differentiates Marek. Genetic add-ons include Androgen Receptor Sensitivity at $500, APOE Genotyping at $200, and MTHFR DNA Analysis at $225. The Lab Builder tool lets a patient assemble a custom panel from “over 100 biomarkers” across hormone, metabolic, inflammation, heart, thyroid, vitamin/mineral, kidney, cancer-screening, genetic, and adrenal categories. That breadth is the deepest in the cash-pay TRT category. Marek also publishes corporate detail confirming the company is a Michigan LLC headquartered in Pontiac.

Where Marek fits: the data-driven patient who wants free T3, free T4, reverse T3, cortisol AM and PM, DHEA-S, IGF-1, ferritin, B12, and a full lipid subfraction at baseline and is willing to pay for the breadth. Where Marek does not fit: the patient who wants the cheapest qualifying-labs-only pathway or who will not engage with the data.

Maximus Tribe: the axis-preservation specialist

Maximus offers the deepest protocol menu of the three. The live catalog (verified 2026-05-28) lists five distinct testosterone pathways: Enclomiphene-Only, Oral Testosterone, Testosterone Cream and Enclomiphene, Injectable TRT, and Injectable TRT and hCG. The site clarifies that injectable TRT can be administered subcutaneously, not just intramuscularly: “Maximus offers subcutaneous injections, which are just as effective as intramuscular and often more comfortable.”

The required lab panel is published verbatim — “Total Testosterone, SHBG (or free testosterone), LH, PSA, and Hematocrit” — and prior bloodwork from the last six months can be uploaded at sign-up if it includes those analytes. Per-protocol dollar pricing was not server-side scrapeable at the time of verification (the page-data JSON shipped a null price field; live pricing lives behind the sign-up widget), and we have flagged per-protocol dollar amounts as needs-direct-confirmation. Promotional copy on 12-month plans is confirmed.

The clinical pitch is axis preservation. Enclomiphene-only works by selectively blocking estrogen feedback at the hypothalamus, raising endogenous LH and FSH and driving the testes to make more testosterone — the HPG axis stays on. That matters for two patient archetypes. The first is the man who wants children in the next 1–3 years and cannot afford the testicular-volume drop and spermatogenesis suppression that injectable cypionate produces. The second is the man with mid-range low T and a functional axis who would rather amplify his own production than supplant it. Injectable TRT plus hCG is the bridge protocol for men who need full-dose exogenous testosterone but want to maintain testicular volume and partial spermatogenesis — hCG mimics LH and keeps the testes producing.

Monthly all-in cost: where the three sit on the price axis

The cash-pay floor for a fully insured patient on standard injectable testosterone cypionate through Blue Cross or a similar plan is roughly $60/month in 2026 — the medication itself is a low-cost generic. The DTC premium is what buys the asynchronous consult, the at-home labs, the 90-day retest cadence, and the willingness to prescribe without the patient ever sitting in a waiting room. Whether that premium is worth $170–$200/month is a function of the patient's schedule, lab-coverage gaps in their insurance, and whether the clinic's formulary matches their preferred protocol.

Patient-fit matrix: who belongs where

• Hone is the right answer for the busy professional with a classic low-T workup. A 38–55-year-old man with morning total T in the 200s, consistent symptoms, and a preference for “ship the kit, ship the script, retest in 90 days” will find Hone's workflow friction-free. The Premium tier's 40+ biomarker panel is broad enough for routine monitoring and shallow enough that the patient is not asked to interpret an adrenal panel they do not need.
• Marek is the right answer for the data-driven optimization patient. The man who tracks his own ferritin, wants free T3 and reverse T3, asks about Androgen Receptor Sensitivity, and is comfortable spending $595 on a single lab panel will get the deepest dataset here. Patients who also want growth-hormone peptides, anastrozole microdosing, or full adrenal monitoring typically pick Marek for the formulary breadth.
• Maximus is the right answer for the fertility-preserving or oligospermia-concerned patient. The Enclomiphene-Only protocol and the Injectable TRT plus hCG bridge are the cleanest cash-pay routes to maintain testicular volume and partial spermatogenesis while still treating low T. Maximus is also the cleanest answer for men with mid-range low T who want to try axis amplification before committing to exogenous testosterone.
• None of the three is the right answer for the obese man with mid-range low T who has not yet tried weight loss. Wittert 2021 T4DM^[3] (n=1,007) showed testosterone undecanoate plus lifestyle beat lifestyle alone for diabetes prevention but did not eliminate the lifestyle requirement. Corona 2013^[7] showed low-calorie diets raised total T by ~2.9 nmol/L and bariatric surgery raised it ~8.7 nmol/L on its own. For this patient archetype, a GLP-1 first — STEP-1 −14.9% TBWL^[4], SURMOUNT-1 −20.9%^[5] — often normalizes T without TRT being needed at all (Corona 2007 obese-hypogonadism mechanism^[6]).

GLP-1 stacking: which clinic also prescribes

All three platforms can stack TRT with GLP-1 therapy, but the integration depth varies. Maximus publishes a dedicated weight-loss line with semaglutide-standard and tirzepatide-standard protocols on the same membership, so a patient can run TRT and a GLP-1 from a single account. Hone treats “weight loss” as one of the protocols included in the Premium membership and has run GLP-1 offerings alongside TRT for several years. Marek's clinical network can incorporate GLP-1 as part of an optimization plan but is less of a single-account consumer-storefront experience for stacked scripts.

For most patients the right sequence is GLP-1 first, then re-measure total T after 10–15% TBWL has been achieved. Many obese hypogonadal men normalize their T into the 350–500 ng/dL range on GLP-1 weight loss alone (Corona 2013^[7]) and never need exogenous testosterone. The patients who still test below 300 ng/dL post-weight-loss are the ones who clearly benefit from adding TRT.

Monitoring rigor: what every TRT clinic should do

Per Endocrine Society 2018 (Bhasin^[1]), every TRT patient should be screened at baseline and at 3, 6, and 12 months for: hematocrit (testosterone can drive secondary erythrocytosis), PSA (testosterone does not cause prostate cancer but can unmask existing disease), estradiol (aromatization can drive gynecomastia and water retention), and a repeat total T plus symptom check. TRAVERSE^[2] added secondary signals worth tracking: atrial fibrillation in patients with prior arrhythmia history, acute kidney injury, and pulmonary embolism. Patients with prior unprovoked VTE should not start TRT.

All three clinics meet this monitoring bar in principle. The differentiator is whether the patient actually shows up for the 3- and 6-month retests — the 90-day cadence baked into Hone Premium is the most patient-friendly default. Marek's breadth makes monitoring easier for patients who want one consolidated lab order. Maximus accepts uploaded prior labs from the last six months, which speeds onboarding but does not change the 3/6/12 retest requirement.

Related research and the broader ranking

• Best TRT clinics 2026 — the full ranked field including Male Excel, Brightmeds, Feel30, Taurus Meds
• TRT and weight loss — what testosterone replacement does and does not do for body composition
• TRT plus GLP-1 stacking — the published evidence for combining testosterone with semaglutide or tirzepatide
• GLP-1 weight loss and erectile dysfunction reversal — the obesity-hypogonadism-ED axis and why weight loss often comes first
• GLP-1 muscle loss prevention — the protein and resistance-training protocol that pairs with any TRT decision

Important disclaimer. This article is educational and does not constitute medical advice. TRT is a prescription therapy with real cardiovascular, hematologic, prostate, and fertility considerations. Diagnosis and treatment should be made by a licensed clinician after confirmatory labs and a full history. Men with prior prostate cancer, untreated severe sleep apnea, active fertility plans, prior unprovoked venous thromboembolism, or uncontrolled heart failure are typically poor candidates for exogenous testosterone. Per-protocol pricing at Marek Health and per-protocol pricing at Maximus Tribe are flagged in this article as needs-direct-confirmation because the respective pages were not server-side scrapeable at the time of verification (2026-05-28); patients should confirm current pricing directly with the clinic before enrollment. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if any of the three clinics materially changes membership pricing, protocol availability, or geographic coverage.